Bristol Myers Squibb to Acquire Turning Point Therapeutics

Bristol Myers Squibb to Acquire Orbital Therapeutics in $1.5 Billion Deal

October 11, 2025

Biotechnology

Bristol Myers Squibb (BMS) has entered into an agreement to acquire Orbital Therapeutics, a privately held biotechnology company developing RNA medicines. The $1.5 billion cash deal will give BMS Orbital’s lead candidate OTX-201 and its proprietary RNA platform, supporting BMS’s efforts to advance in vivo CAR T and immunotherapy approaches.

Bristol Myers Squibb to Acquire Karuna Therapeutics in $14.0B Deal

December 22, 2023

Pharmaceuticals

Bristol Myers Squibb (BMS) and Karuna Therapeutics entered into a definitive merger agreement under which BMS will acquire Karuna for $330 per share in cash, valuing Karuna’s equity at about $14.0 billion (about $12.7 billion net of estimated cash acquired). The deal is expected to close in the first half of 2024, subject to customary approvals and regulatory conditions.

Bristol Myers Squibb to Acquire Mirati Therapeutics in $4.8B Cash-and-CVR Deal

October 13, 2023

Pharmaceuticals

Bristol Myers Squibb has entered into a definitive merger agreement to acquire Mirati Therapeutics for $58 per share in cash, valuing the transaction at $4.8 billion in equity value. The deal also includes a non-tradeable contingent value right (CVR) that could provide up to an additional $1 billion of value tied to regulatory acceptance of an NDA for Mirati’s MRTX1719.

Bristol Myers Squibb Acquires RayzeBio for $4.1 Billion

December 26, 2023

Healthcare Services

Bristol Myers Squibb (BMS) and RayzeBio have announced a definitive merger agreement under which BMS will acquire RayzeBio for $62.50 per share in cash, valuing the equity at approximately $4.1 billion. The deal is expected to close in the first half of 2024, subject to customary closing conditions.

Turnstone Biologics Acquires Myst Therapeutics

January 20, 2021

Biotechnology

Turnstone Biologics Corp., a privately held clinical-stage biotechnology company, has acquired California-based Myst Therapeutics to integrate Myst’s tumor-infiltrating lymphocyte (TIL) selection and expansion platform into Turnstone’s oncolytic virus and cell therapy pipeline. The acquisition grants Turnstone full access to Myst’s R&D capabilities, development collaborations, and a TIL program with a lead candidate expected to enter the clinic soon; financial terms were not disclosed.

Spero Health Acquires My Turning Point

October 3, 2022

Healthcare Services

Spero Health, a PE-backed national outpatient addiction treatment provider, has acquired My Turning Point, a Kentucky-based outpatient addiction treatment program with four clinic locations (Stanford, Russell Springs, Nicholasville and Cynthiana). The deal expands Spero's network across Kentucky and increases local capacity for medication‑assisted and integrated behavioral health services.